PTGX in the 13F filings
Protagonist Therapeutics Inc · CUSIP 74366E102
- Quarter end
- 30 Jun 2026
- the date the book describes
- Filed
- 27 Oct 2026
- latest of these filings; the earliest 3 Aug 2026
- Managers listing it
- 24
- at least, of 95 tracked, among listed positions
- Comparable managers
- 91
- filed both Q1 2026 and Q2 2026; 9 listed it in both
- Shares listed
- 19,213,456
- combined, among listed positions
- Reported value
- $2.4bn
- combined, at the quarter end
AllianceBernstein LP. Values in this filing are at the previous quarter end's prices; its share count is the quarter end's.
Among the 91 comparable managers: 14 buyers (opened or added shares) and 10 sellers (trimmed or exited), at least, among listed positions. Their net change in shares was -2,468,482.
Managers listing PTGX in Q2 2026
24 of 24 holders
Largest increases and reductions, by shares
Increases
- T. Rowe Price Associates Incexisting position · 2,149,662 shares now+484,165
- Invesco Ltdexisting position · 2,340,667 shares now+175,997
- Neuberger Berman Group LLCexisting position · 302,427 shares now+160,986
- Arrowstreet Capital LPnew position · 44,529 shares now+44,529
- Schonfeld Strategic Advisors LLCnew position · 28,072 shares now+28,072
Reductions
- Janus Henderson Group Ltdexisting position · 2,129,780 shares now-761,747
- Marshall Wace LLPexisting position · 109,017 shares now-519,058
- Holocene Advisors LPexisting position · 8,495 shares now-201,421
- Wellington Management Group LLPexisting position · 3,416,781 shares now-182,863
- Susquehanna International Group LLPexisting position · 57,062 shares now-110,514
New positions and exits
New (6)
Exited (2)
- Citadel Advisors LLCwas $164m
- Hudson Bay Capital Management LPwas $396k
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q1 2017 | 1 | $231k | n.a. | n.a. |
| Q2 2017 | 1 | $197k | n.a. | n.a. |
| Q3 2017 | 1 | $458k | n.a. | n.a. |
| Q4 2017 | 2 | $19m | n.a. | n.a. |
| Q1 2018 | 1 | $8.7m | n.a. | n.a. |
| Q2 2018 | 2 | $6.5m | n.a. | n.a. |
| Q3 2018 | 1 | $23m | n.a. | n.a. |
| Q4 2018 | 2 | $15m | n.a. | n.a. |
| Q1 2019 | 2 | $23m | n.a. | n.a. |
| Q2 2019 | 3 | $20m | n.a. | n.a. |
| Q3 2019 | 2 | $18m | n.a. | n.a. |
| Q4 2019 | 1 | $11m | n.a. | n.a. |
| Q1 2020 | 1 | $11m | n.a. | n.a. |
| Q2 2020 | 2 | $48m | n.a. | n.a. |
| Q3 2020 | 1 | $54m | n.a. | n.a. |
| Q4 2020 | 2 | $60m | n.a. | n.a. |
| Q1 2021 | 2 | $87m | n.a. | n.a. |
| Q2 2021 | 2 | $156m | n.a. | n.a. |
| Q3 2021 | 4 | $130m | n.a. | n.a. |
| Q4 2021 | 4 | $169m | n.a. | n.a. |
| Q1 2022 | 3 | $110m | n.a. | n.a. |
| Q2 2022 | 5 | $67m | n.a. | n.a. |
| Q3 2022 | 3 | $53m | n.a. | n.a. |
| Q4 2022 | 5 | $52m | n.a. | n.a. |
| Q1 2023 | 4 | $116m | n.a. | n.a. |
| Q2 2023 | 5 | $171m | n.a. | n.a. |
| Q3 2023 | 2 | $109m | n.a. | n.a. |
| Q4 2023 | 2 | $191m | 2 | 0 |
| Q1 2024 | 5 | $248m | 4 | 1 |
| Q2 2024 | 3 | $262m | 2 | 2 |
| Q3 2024 | 3 | $286m | 2 | 1 |
| Q4 2024 | 4 | $253m | 3 | 0 |
| Q1 2025 | 4 | $354m | 3 | 1 |
| Q2 2025 | 5 | $425m | 4 | 1 |
| Q3 2025 | 8 | $790m | 8 | 0 |
| Q4 2025 | 10 | $1.3bn | 14 | 14 |
| Q1 2026 | 9 | $1.8bn | 16 | 10 |
| Q2 2026 | 7 | $1.9bn | 14 | 10 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
PTGX and LLY →PTGX and JNJ →PTGX and VRTX →Choose a stock to compare with PTGX →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own PTGX, latest filings →Back to the 13F Explorer →